Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Benefits of some cancer drugs exaggerated because trials were stopped early

Italian scientists say the benefits of some cancer drugs may be exaggerated as a rising number of trials are stopped early.

9 Apr 2008

Kidney cancer surgery often determined by surgeons' practice style, not medical factors

A new study reveals that the type of surgery a patient with kidney cancer receives depends more on the surgeon's preference than on the patient's tumor size, demographic characteristics, or general medical health.

11 Mar 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

Kidney cancer drug attacks a major type of acute myeloid leukemia

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.

30 Jan 2008

New method for presenting clinical trial survival data

Researchers have developed a new method for presenting clinical trial survival data that includes data from all trial participants unlike the standard method, according to a commentary published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

UK study looks at obesity in women

The study shows that overweight and obese women in the UK are at a higher risk of developing and dying from cancer.

6 Nov 2007

Cancer risks for overweight women

Half of all cases of womb cancer and a type of oesophageal cancer in women are caused by being overweight or obese, according to a new report published online in the British Medical Journal.

6 Nov 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer.

4 Oct 2007

Axitinib shows promise for patients with advanced kidney cancer

Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

27 Sep 2007

Moderate drinkers less likely to get kidney cancer

The researchers at the Karolinska Institute in Stockholm suggest that people who drink 22 ounces of alcohol a week are 40 percent less likely to develop kidney cancer.

28 Aug 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Kidney removed through belly button

Surgeons specializing in laparoscopic procedures at UT Southwestern Medical Center have successfully removed a patient's kidney by performing a unique nephrectomy entirely through the belly button.

23 Aug 2007

Drug topotecan shows promise against Wilms tumor

St. Jude researchers have shown that the drug topotecan holds promise as a treatment for the recurrent form of a kidney cancer called Wilms tumor, a solid tumor of the kidney that arises from immature kidney cells, and the fifth most common tumor among children.

17 Aug 2007

Reactivating a critical gene lost in kidney cancer reduces tumor growth

Researchers at Mayo Clinic Jacksonville, have found that a key gene is often silenced in clear cell renal cell carcinoma, the most common type of kidney cancer, and when they restored that gene in human kidney cancer cells in culture and animal experiments, tumors stopped growing and many disappeared.

17 Aug 2007

First biomarker discovered that predicts prostate cancer outcome

Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery.

17 Aug 2007

Light-activated molecules used to induce apoptosis in cancer cells

A key challenge facing doctors as they treat patients suffering from cancer or other diseases resulting from genetic mutations is that the drugs at their disposal often don't discriminate between healthy cells and dangerous ones -- think of the brute-force approach of chemotherapy, for instance.

12 Aug 2007